Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell?

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) fell 6.9% during trading on Tuesday . The stock traded as low as $14.91 and last traded at $14.85. 1,102,830 shares traded hands during trading, an increase of 27% from the average session volume of 865,084 shares. The stock had previously closed at $15.95.

Analyst Ratings Changes

Several brokerages recently commented on CAPR. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Cantor Fitzgerald upped their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Down 6.5 %

The firm has a market cap of $678.41 million, a P/E ratio of -14.08 and a beta of 4.08. The company’s 50 day simple moving average is $14.17 and its 200-day simple moving average is $13.09.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund lifted its stake in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the period. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.